Business
Precigen Reports Second Quarter and First Half 2021 Financial Results
- Company to provide comprehensive clinical pipeline and data updates at R&D call on November 4th - GERMANTOWN, Md., Aug. 9, 2021 /PRNewswire/ -- Precigen,
About this update from Precigen, Inc.
[{"type":"text","content":"- Company to provide comprehensive clinical pipeline and data updates at R&D call on November 4th -\n\n\nGERMANTOWN, Md., Aug. 9, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2021 financial results. \n\n \n \n \n \n \n \n\n \n\"We have made significant progress in the first half of 2021 and are well on our way to meet or exceed the goals we set at the beginning of the year. We are excited about the advancement of our portfolio and look forward to providing further clinical updates and data readouts at a planned R&D call on November 4th as well as at medical congresses in the fourth quarter of the year,\" said Helen Sabzevari, PhD, President and CEO of Precigen. \"We see 2021 as a pivotal year for the UltraCAR-T, ActoBiotics and AdenoVerse platforms with significant new clinical data on our most advanced therapeutic candidates from these core therapeutic platforms.\"\nBusiness Highlights:\nR&D Update Call\nPrecigen will host an R&D call on November 4th that will be dedicated to reviewing progress made in advancing the Company's clinical pipeline, including the latest data for several of our key programs. PRGN-3005 UltraCAR-T®\nPRGN-3005 UltraCAR-T is a first-in-class investigational therapy under evaluation in a Phase 1/1b clinical trial for the treatment of patients with advanced, recurrent platinum resistant ovarian cancer. Study subjects receive the PRGN-3005 infusion either via intraperitoneal (IP) (Arm A) or intravenous (IV) (Arm B) infusion. Preliminary Phase 1 data previously reported from the two lowest dose levels of the IP arm showed a favorable safety profile with no dose-limiting toxicities (DLTs), neurotoxicity or cytokine release syndromes (CRS); encouraging expansion and persistence without lymphodepletion; and clinical activity as evidenced by regression in total target tumor burden. The dose escalation phase of both the IP and IV arms of the trial is ongoing concurrently. Enrollment in dose level 4 of the IP arm and dose level 3 of the IV arm is ongoing. The Company anticipates the presentation of interim data from the Phase 1 trial in the fourth quarter of 2021.PRGN-3006 UltraCAR-T®\nPRGN-3006 UltraCAR-T is a first-in-class invest...